These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 7201835)

  • 21. [Gas analysis and pH-measurements in pleural effusions (author's transl)].
    Szüle P; Wollák A
    Z Erkr Atmungsorgane; 1981; 156(1):40-3. PubMed ID: 6784360
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of malignant effusions on methotrexate disposition.
    Li J; Gwilt P
    Cancer Chemother Pharmacol; 2002 Nov; 50(5):373-82. PubMed ID: 12439595
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Importance of pharmacokinetic studies on cyclophosphamide (NSC-26271) in understanding its cytotoxic effect.
    Donelli MG; Bartosek I; Guaitani A; Martini A; Colombo T; Pacciarini MA; Modica R
    Cancer Treat Rep; 1976 Apr; 60(4):395-401. PubMed ID: 1277213
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Biological significance of fibrinopeptide A elevation in the blood].
    Mombelli G; Hofmann V; Straub PW
    Schweiz Med Wochenschr; 1977 Dec; 107(48):1779-81. PubMed ID: 579262
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vascular endothelial growth factor levels in post-CABG pleural effusions are associated with pleural inflammation and permeability.
    Kalomenidis I; Stathopoulos GT; Barnette R; Papiris S; Blackwell TS; Roussos C; Light RW
    Respir Med; 2007 Feb; 101(2):223-9. PubMed ID: 16854577
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Potential diagnostic value of methylation profile in pleural fluid and serum from cancer patients with pleural effusion.
    Benlloch S; Galbis-Caravajal JM; Martín C; Sanchez-Paya J; Rodríguez-Paniagua JM; Romero S; Mafe JJ; Massutí B
    Cancer; 2006 Oct; 107(8):1859-65. PubMed ID: 16983705
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Relationships among tumor burden, tumor size, and the changing concentrations of fibrin degradation products and fibrinolytic factors in the pleural effusions of rabbits with VX2 lung tumors.
    Hatton MW; Southward SM; Ross BL; Clarke BJ; Singh G; Richardson M
    J Lab Clin Med; 2006 Jan; 147(1):27-35. PubMed ID: 16443002
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Differential diagnosis between exudate and transudate in pleural effusion].
    Vázquez F; Michelángelo H; Trevisani H; González F; de Quiros B
    Medicina (B Aires); 1996; 56(3):223-30. PubMed ID: 9035477
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enzymatic toxicogenation of "activated" cyclophosphamide by 3'-5' exonucleases.
    Bielicki L; Voelcker G; Hohorst HJ
    J Cancer Res Clin Oncol; 1983; 105(1):27-9. PubMed ID: 6300134
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Comparison of the diagnostic value of telomerase activity with CEA level in benign and malignant pleural effusions].
    Yang Z; Xie C
    Zhonghua Jie He He Hu Xi Za Zhi; 2001 Apr; 24(4):201-3. PubMed ID: 11802962
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical pharmacokinetics of cyclophosphamide and metabolites with and without SR-2508.
    Chan KK; Hong PS; Tutsch K; Trump DL
    Cancer Res; 1994 Dec; 54(24):6421-9. PubMed ID: 7987837
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gelatinolytic activities (matrix metalloproteinase-2 and -9) and soluble extracellular domain of Her-2/neu in pleural effusions.
    Di Carlo A; Mariano A; Terracciano D; Mazzarella C; Galzerano S; Cicalese M; Cecere C; Macchia V
    Oncol Rep; 2007 Aug; 18(2):425-31. PubMed ID: 17611666
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cystatin C of pleural effusion as a novel diagnostic aid in pleural diseases of different aetiologies.
    Domej W; Tilz GP; Földes-Papp Z; Demel U; Rabold T; Holzer H
    Clin Sci (Lond); 2002 Mar; 102(3):373-80. PubMed ID: 11869179
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease.
    Kraft A; Weindel K; Ochs A; Marth C; Zmija J; Schumacher P; Unger C; Marmé D; Gastl G
    Cancer; 1999 Jan; 85(1):178-87. PubMed ID: 9921991
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Urinary elimination of cyclophosphamide alkylating metabolites and free thiols following two administration schedules of high-dose cyclophosphamide and mesna.
    Fleming RA; Cruz JM; Webb CD; Kucera GL; Perry JJ; Hurd DD
    Bone Marrow Transplant; 1996 Apr; 17(4):497-501. PubMed ID: 8722345
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Deactivation of cyclophosphamide (NSC-26271) metabolites by sulfhydryl compounds.
    Draeger J; Peter G; Hohorst HJ
    Cancer Treat Rep; 1976 Apr; 60(4):355-9. PubMed ID: 1277211
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Implantable central venous access ports for minimally invasive repetitive drainage of pleural effusions.
    Alisky JM
    Med Hypotheses; 2007; 68(4):910-1. PubMed ID: 17234354
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evidence for peroxidase-mediated metabolism of cyclophosphamide.
    Kanekal S; Kehrer JP
    Drug Metab Dispos; 1993; 21(1):37-42. PubMed ID: 8095224
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pleural effusion and serum soluble fas-ligand levels are elevated in different clinical conditions.
    Wang PS; Chen YM; Hsieh YL; Yu CF; Tsai CM; Perng RP
    Lung; 2002; 180(1):25-32. PubMed ID: 12105754
    [TBL] [Abstract][Full Text] [Related]  

  • 40. D-dimer levels in pleural effusions.
    Dikensoy O; Stathopoulos GT; Zhu Z; Light RW
    Respir Med; 2006 Aug; 100(8):1337-41. PubMed ID: 16427265
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.